Oliver Buck

GAIASO Theranostics exists to change outcomes in women’s cancers by developing more effective therapies, ultimately delivering longer, healthier and more dignified lives. We’re closing the gender gap in oncology by advancing a new generation of radiotheranostics. Built on the Affilin® protein-engineering platform and developed with our partners at PreMIT Pty Ltd, our programs combine precise tumour targeting, optimised biodistribution, and rational combinations to enhance efficacy. Our urgent mission is to accelerate life-saving options for more women, worldwide.

Connect is a different kind of utility company with one simple goal: to improve the efficiency, sustainability and reliability of Canada’s thermal energy systems one building at a time. We're a privately held company that acquires, operates and maintains top quality, energy efficient HVAC systems. As one of Canada’s top independent thermal energy distribution companies, we help clients offset their costs by taking on the ownership, duties and responsibilities of in-building thermal energy systems, while simultaneously providing our customers with worry-free contracts, fair pricing, and friendly, reliable service.

Navigo Proteins discovers and develops novel scaffold proteins-based affinity ligands for commercial biologics GMP purification or as biopharmaceutical drugs/binders. They are all small, stable, highly engineerable, selective, and economically, homogeneously producible. In PRECISION CAPTURING a protein A-like scaffold serves for an antibody-like capture step even of non-Fc bearing molecules. In PRECISION TARGETING human ubiquitin is the basis for highly selective Affilin® ligands as part of a broad range of biopharmaceutical drugs. Navigo Proteins’ unique protein engineering expertise is the basis a world-wide unique, versatile scaffold proteins platform. Our robust, rapid and reliable high-throughput-based, robotics assisted platform designs, produces, analyzes and selects suitable affinity ligand proteins, optimized for their tasks in industrial downstream processing or as biopharmaceutical drugs. PRECISION CAPTURING creates custom ligands against any biologic, Fc-independent, and enables antibody-like affinity downstream processes, with competitive binding capacities, caustic stabilities, usage-cycles, flow rates and commercially available off-the-shelf leaching assays. It is applicable for purifying any recombinant protein, mAb, virus, VLP, cell, etc. Navigo Proteins has established partnerships with Repligen Corp. to convert its custom affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing. Our PRECISION TARGETING platform creates tailored ligands which bind any desired biologic in biopharmaceutical or in diagnostic use, e.g. radiopharmaceuticals, Protein-drug-conjugates, CAR-T ligands or theranostics, in which the same Affilin® binder is employed in diagnosis, treatment and treatment-monitoring. Navigo Proteins is about 50 heads strong, steadily growing and based in Halle, S/W of Berlin. We offer our expertise to interested pharma, biotech and life sciences companies. https://www.navigo-proteins.com/imprint

OncoBeta® GmbH located in Garching near Munich is a manufacturer and service provider of innovative medical solutions specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotopes. We are very proud to be a pioneer and innovator in the epidermal radioisotope sector, presently offering a therapeutic application for physicians to treat non-melanoma skin cancer. Our current flag ship solution is the Rhenium-SCT® (Skin Cancer Therapy) a novel treatment option for basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs) based on the local irradiation of tumors with the beta-emitter Rhenium-188. Rhenium-188 is an optimal isotope for the treatment of superficial lesions such as non-melanoma skin cancers due to its practical penetration of 2-3mm in human tissue. Since the radioactive Rhenium does not come in direct contact with the patient, the Rhenium-SCT® is seen as a patient-personalised brachytherapy with minimal radiation exposition and adverse effects. The Rhenium-SCT is a CE certified method arising from over 10 years of experience and clinical studies (>700 patients, >1900 lesions). It provides non-melanoma skin cancer patients with a single-session, painless, highly-effective non- surgical treatment with excellent aesthetic results and complete remissions in up to 98,5% of all cases. We are also currently evaluating further exciting applications and treatment possibilities with rhenium-188.

MetaOptima: empowering users with advanced technologies MetaOptima is a digital health tech company dedicated to revolutionizing the dermatology and skin care industry with affordable, effective and intelligent tools. In order to provide state-of-the-art care, both medical professionals and their patients should be equipped with advanced tools. We are proud to offer two products designed to enhance the quality of patient care and organization while streamlining services for maximum efficiency: DermEngine and MoleScope. DermEngine is an intelligent skin analytics platform designed to provide medical experts with smart technologies to enhance workflows, organization and communications. MoleScope is a digital dermoscopic attachment for smartphones/tablets that allows users to take medical grade quality images of their skin. Here at MetaOptima, we take pride in our bold vision to bring digital healthcare and mobile technologies together to save lives and contribute to better health outcomes. We work hard to build a successful company with strong values and sense of community, as well as create jobs and develop tools that make the world a better place for patients, doctors, and businesses.

GAIASO Theranostics exists to change outcomes in women’s cancers by developing more effective therapies, ultimately delivering longer, healthier and more dignified lives. We’re closing the gender gap in oncology by advancing a new generation of radiotheranostics. Built on the Affilin® protein-engineering platform and developed with our partners at PreMIT Pty Ltd, our programs combine precise tumour targeting, optimised biodistribution, and rational combinations to enhance efficacy. Our urgent mission is to accelerate life-saving options for more women, worldwide.

Our mission is to build a global community of entrepreneurs, international philanthropists, medical and scientific experts, and patients which challenges the “one size fits all" model and promotes a paradigm shift in cancer treatment. Our goal “Aegroti Salus suprema lex ” (The Benefit of the Patient is the Highest Law) is to enable a growing number of cancer patients worldwide to gain access to highly effective, personalized, and standardized theranostic treatments in Precision Oncology. We achieve this through our international network of centers for Precision Oncology, running the International Academy for Precision Oncology, supporting scientific and technological development, and establishing ICPO Reference and Training Centers. Please join us on this remarkable journey!

Connect is a different kind of utility company with one simple goal: to improve the efficiency, sustainability and reliability of Canada’s thermal energy systems one building at a time. We're a privately held company that acquires, operates and maintains top quality, energy efficient HVAC systems. As one of Canada’s top independent thermal energy distribution companies, we help clients offset their costs by taking on the ownership, duties and responsibilities of in-building thermal energy systems, while simultaneously providing our customers with worry-free contracts, fair pricing, and friendly, reliable service.

Navigo Proteins discovers and develops novel scaffold proteins-based affinity ligands for commercial biologics GMP purification or as biopharmaceutical drugs/binders. They are all small, stable, highly engineerable, selective, and economically, homogeneously producible. In PRECISION CAPTURING a protein A-like scaffold serves for an antibody-like capture step even of non-Fc bearing molecules. In PRECISION TARGETING human ubiquitin is the basis for highly selective Affilin® ligands as part of a broad range of biopharmaceutical drugs. Navigo Proteins’ unique protein engineering expertise is the basis a world-wide unique, versatile scaffold proteins platform. Our robust, rapid and reliable high-throughput-based, robotics assisted platform designs, produces, analyzes and selects suitable affinity ligand proteins, optimized for their tasks in industrial downstream processing or as biopharmaceutical drugs. PRECISION CAPTURING creates custom ligands against any biologic, Fc-independent, and enables antibody-like affinity downstream processes, with competitive binding capacities, caustic stabilities, usage-cycles, flow rates and commercially available off-the-shelf leaching assays. It is applicable for purifying any recombinant protein, mAb, virus, VLP, cell, etc. Navigo Proteins has established partnerships with Repligen Corp. to convert its custom affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing. Our PRECISION TARGETING platform creates tailored ligands which bind any desired biologic in biopharmaceutical or in diagnostic use, e.g. radiopharmaceuticals, Protein-drug-conjugates, CAR-T ligands or theranostics, in which the same Affilin® binder is employed in diagnosis, treatment and treatment-monitoring. Navigo Proteins is about 50 heads strong, steadily growing and based in Halle, S/W of Berlin. We offer our expertise to interested pharma, biotech and life sciences companies. https://www.navigo-proteins.com/imprint